This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Santoro, D. Articles by Ferrannini, E. Search for Related Content PubMed PubMed Citation Articles by Santoro, D. Articles by Ferrannini, E.

Hypertension, Vol 20, 181-191, Copyright © 1992 by American Heart Association

ARTICLES

Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension

D Santoro, A Natali, C Palombo, LS Brandi, M Piatti, S Ghione and E Ferrannini
Metabolism Unit, C.N.R. Institute of Clinical Physiology, Pisa, Italy.

The relation between the renin-angiotensin-aldosterone (RAA) system and carbohydrate metabolism and insulin sensitivity in essential hypertension has not been investigated systematically. Twenty nondiabetic patients (age, 49 +/- 1 years; body mass index (BMI), 26.1 +/- 0.4 kg/m2) with essential hypertension (blood pressure, 155 +/- 3/105 +/- 1 mm Hg) received an oral glucose tolerance test (OGTT) at the end of a 1-month placebo period and again monthly during 3 months of angiotensin converting enzyme (ACE) inhibition (cilazapril, 5 mg/day). Furthermore, a two-step euglycemic insulin clamp was performed after placebo and again at the end of treatment. Blood pressure fell by 7 +/- 4/10 +/- 3 mm Hg (p less than 0.001), while BMI remained stable. On the euglycemic clamp, insulin-mediated (plasma insulin, 470 pM) whole body glucose use averaged 42.5 +/- 1.6 mumol.min-1.kg-1 before and 43.6 +/- 1.9 after ACE inhibition (p = NS). Substrate concentrations and oxidative rates and energy expenditure (as estimated by indirect calorimetry) were not altered by ACE inhibition, either in the fasting state or in response to insulin. In contrast, oral glucose tolerance was significantly (p less than 0.05) improved after treatment (area under OGTT curve (AUC), 240 +/- 24 versus 282 +/- 23 mmol 2 hr.l- 1). The latter change was associated with enhanced (+16%, p less than 0.05) insulin responsiveness to glucose (estimated as the insulin AUC divided by the glucose AUC) throughout the 3 months of ACE inhibition. At baseline, both the OGTT and the clamp had a marked hypokalemic effect (mean decrements in plasma potassium of 0.75 +/- 0.05 and 0.92 +/- 0.05 mmol/l, respectively) in association with plasma aldosterone reductions of 30% and 50%. Chronic ACE inhibition caused a further 20% (p less than 0.03) lowering of plasma aldosterone concentrations but attenuated insulin-induced hypokalemia. Plasma sodium, which was unaltered by the pretreatment tests, fell during the posttreatment tests (by 3 mmol/l, p less than 0.001). In the urine, the ratio of the fractional excretion of potassium to that of sodium was decreased by both oral glucose (-22%, p less than 0.01) and ACE inhibition (-21%, p less than 0.001). Higher plasma potassium levels before treatment predicted a better blood pressure response to ACE inhibition (r = 0.60, p less than 0.005).(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				D. K McGuire, J. R Winterfield, J. A Rytlewski, and E. Ferrannini Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus Diabetes and Vascular Disease Research, March 1, 2008; 5(1): 59 - 66. [Abstract] [PDF]

				C. Fava, M. Montagnana, L. Rosberg, P. Burri, P. Almgren, A. Jonsson, P. Wanby, G. Lippi, P. Minuz, L.U. Hulthen, et al. Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure Hum. Mol. Genet., February 1, 2008; 17(3): 413 - 418. [Abstract] [Full Text] [PDF]

				T. Rosenthal, E. Rosenmann, D. Tomassoni, and F. Amenta Effect of Lercanidipine on Kidney Microanatomy in Cohen-Rosenthal Diabetic Hypertensive Rats Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 145 - 152. [Abstract] [PDF]

				F. Amenta, E. Peleg, D. Tomassoni, M. Sabbatini, and T. Rosenthal Effect of Treatment With Lercanidipine on Heart of Cohen-Rosenthal Diabetic Hypertensive Rats Hypertension, June 1, 2003; 41(6): 1330 - 1335. [Abstract] [Full Text] [PDF]

				J. R. Petrie, A. D. Morris, S. Ueda, M. Small, R. Donnelly, J. M. C. Connell, and H. L. Elliott Trandolapril Does Not Improve Insulin Sensitivity in Patients with Hypertension and Type 2 Diabetes: A Double-Blind, Placebo-Controlled Crossover Trial J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1882 - 1889. [Abstract] [Full Text]

				T.-C. Fang and W.-C. Huang Angiotensin Receptor Blockade Blunts Hyperinsulinemia-Induced Hypertension in Rats Hypertension, August 1, 1998; 32(2): 235 - 242. [Abstract] [Full Text] [PDF]

				T. Rosenthal, Y. Erlich, E. Rosenmann, and A. Cohen Effects of Enalapril, Losartan, and Verapamil on Blood Pressure and Glucose Metabolism in the Cohen-Rosenthal Diabetic Hypertensive Rat Hypertension, June 1, 1997; 29(6): 1260 - 1264. [Abstract] [Full Text]

				M. W. Brands, D. L. Harrison, H. L. Keen, A. Gardner, E. W. Shek, and J. E. Hall Insulin-Induced Hypertension in Rats Depends on an Intact Renin-Angiotensin System Hypertension, April 1, 1997; 29(4): 1014 - 1019. [Abstract] [Full Text]